bluebird bio, headquartered in Cambridge, Mass., announced it will have a ribbon-cutting ceremony at its new gene therapy factory in Durham, NC. The manufacturing plant will produce lentiviral vectors for its gene and cell therapies, including bb2121 and bb21217 for multiple myeloma and possibly LentiGlobin for transfusion-dependent beta-thalassemia (TDT) and sickle cell disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,